Cocrystal Pharma
We have identified promising small molecule antiviral therapeutics that target the replication process of influenza viruses, noroviruses, coronaviruses, and rhinoviruses. We are currently conducting a Phase 1b challenge study evaluating our pan-viral protease inhibitor CDI-988 as a norovirus preventive and treatment, following favorable safety and tolerability data from our Phase 1 study. CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus
Basic Information
- Category: business
- Founded: 2009
- Website: https://www.cocrystalpharma.com
Documented Facts
- Email: header-logo@2x.png (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: COCP (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Cocrystal Pharma — Official Site (official)
- Cocrystal Pharma on facebook (social)
- Cocrystal Pharma on linkedin (social)
- Cocrystal Pharma, Inc. — SEC EDGAR (reference)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Cocrystal Pharma.
- Canonical profile: https://brandsource.ai/brands/cocrystal-pharma
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/cocrystal-pharma/json-ld
- Citation profile API: https://brandsource.ai/api/brands/cocrystal-pharma/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We have identified promising small molecule antiviral therapeutics that target the replication process of influenza viruses, noroviruses, coronaviruses, and rhinoviruses. We are currently conducting a Phase 1b challenge study evaluating our pan-viral protease inhibitor CDI-988 as a norovirus preventive and treatment, following favorable safety and tolerability data from our Phase 1 study. CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 3 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.